Gilead Stock 2021: Why The Biotech Stock Isn't Depending On Covid Drugs

Gilead Stock 2021: Why The Biotech Stock Isn't Depending On Covid Drugs

Gilead Sciences isn't betting its 2021 on coronavirus treatment Veklury. But the biotech company still sees plenty of catalysts in oncology, virology and inflammation for Gilead stock.